Lily Zou, PhD, MBA, is the Co-founder and CEO of Degron Therapeutics. She is a seasoned executive with scientific knowledge in drug discovery and development, and extensive business and commercial expertise. Dr. Zou led Degron in successful capital raise, expanding its platform, and advancing its pipeline programs.

Prior to joining Degron, Dr. Zou served as CEO of Fosun Pharma USA, Vice President of Fosun Pharma Group, Healthcare Partner of Fosun Pharma, and Chairman of the Board or Board member of four Fosun-invested companies. Dr. Zou built and grew Fosun Pharma’s US business and founded Fosun Pharma’s incubator, Boston-based Fusion Bioventures, which invests and incubates early-stage biotech companies. Dr. Zou also built a sales and marketing team in the USA for Fosun Pharma drugs and diagnostics, and launched Fosun Pharma’s first products in 2019.

Prior to working at Fosun, Dr. Zou worked at a top management consulting firm (Bain), in large pharma companie (Novartis/Sandoz, Wyeth, Millennium), and small biotech startups (ArQule, Coley)

Dr. Zou received a BS from Beijing University, a PhD in Microbiology and Immunology from Cornell University, and an MBA from MIT Sloan School of Management.